X
Xin Zhang
Researcher at China Pharmaceutical University
Publications - 23
Citations - 710
Xin Zhang is an academic researcher from China Pharmaceutical University. The author has contributed to research in topics: Inflammasome & PI3K/AKT/mTOR pathway. The author has an hindex of 12, co-authored 23 publications receiving 413 citations.
Papers
More filters
Journal ArticleDOI
Nuclear Factor E2-Related Factor-2 Negatively Regulates NLRP3 Inflammasome Activity by Inhibiting Reactive Oxygen Species-Induced NLRP3 Priming
TL;DR: Nrf2 negatively regulating NLRP3 inflammasome activity by inhibiting the priming step was demonstrated and it was suggested that Nrf2 could be a potential target for some uncontrolled inflammaome activation-associated diseases.
Journal ArticleDOI
Dimethyl fumarate ameliorates dextran sulfate sodium-induced murine experimental colitis by activating Nrf2 and suppressing NLRP3 inflammasome activation.
TL;DR: The ability of DMF to inhibit NLRP3 inflammasome activation and its potential use in the treatment ofNLRP3-associated diseases was demonstrated and increased glutathione induced by DMF demonstrated its potential antioxidant capacity.
Journal ArticleDOI
Jujuboside A promotes Aβ clearance and ameliorates cognitive deficiency in Alzheimer's disease through activating Axl/HSP90/PPARγ pathway.
Mu Zhang,Cheng Qian,Zu-Guo Zheng,Fei Qian,Yanyan Wang,Pyone Myat Thu,Xin Zhang,Ya-Ping Zhou,Li-Fan Tu,Qingling Liu,Hui-Jun Li,Hua Yang,Ping Li,Xiaojun Xu +13 more
TL;DR: This study suggests that the up-regulation of HSP90β by JuA through Axl is a potential therapeutic strategy to facilitate Aβ42 clearance and ameliorate cognitive deficiency in AD.
Journal ArticleDOI
Gen-27, a newly synthesized flavonoid, inhibits glycolysis and induces cell apoptosis via suppression of hexokinase II in human breast cancer cells
Lei Tao,Libing Wei,Yishi Liu,Yang Ding,Xiuting Liu,Xin Zhang,Xiaoping Wang,Yuyuan Yao,Jinrong Lu,Qing Wang,Rong Hu +10 more
TL;DR: The results showed that Gen‐27 had significant anticancer effects against human breast cancer and it may potentially be used as a novel anticancer agent for the treatment of breast cancer.
Journal ArticleDOI
Oroxylin A inhibits colitis by inactivating NLRP3 inflammasome
TL;DR: Oroxylin A inhibits colitis by inactivating NLRP3 inflammasome with high affinity for Na6(CO3)(SO4)2, Na2SO4.